




INTRODUCTION

Efgartigimod Mechanism of Action: Blocking FcRn



- ADAPT NXT is a phase 3B, randomized, open-label, parallel-group study designed to evaluate 2 dosing regimens of efgartigimod IV to maximize and maintain clinical benefit in participants with gMG maintain its high serum concentration¹ Both study arms initially receive 1 cycle of 4 once-weekly infusions. Subsequently, the Fixed Cycles arm receives 3 - FcRn is additionally involved in other cellular cycles of 4 once-weekly infusions (with 4 weeks between cycles), and the Q2W arm receives infusions once every processes such as albumin recycling, as well other week as IgG-dependent phagocytosis and antigen presentation² Part A (21 weeks) Efgartigimod is a human IgG1 Fc fragment, adapt a natural ligand of FcRn, engineered to have myasthenia gravis study Efgartigimod IV 10 mg/kg, Fixed Cycles (n=17) increased affinity for FcRn and outcompete endogenous IgG^{3,4} **Entry criteria** Adults (≥18 years) with AChR-Ab+ gMG Efgartigimod binding to FcRn prevents IgG recycling and promotes its lysosomal degradation, ■ MG-ADL score ≥5 Efgartigimod IV 10 mg/kg, Q2W (n=52) reducing IgG levels without impacting IgG (>50% nonocular) production³⁻⁶ MGFA Class II, III, or IV - Targeted reduction of all IgG subtypes 3,5 Concomitant gMG - No impact on levels of IgM, IgA, IgE, or $IgD^{3,6}$

- FcRn recycles IgG to extend its half-life and

- No reduction in albumin or increase in cholesterol levels⁵⁻⁷

RESULTS

Table 1. ADAPT NXT Baseline Demographics and Clinical Characteristics Safety Analysis Set			Table 2. ANCOVA ^a Analysis of Primary Endpoint: Mean of the Average MG-ADL Total Score Change From Baseline During Week 1-21											
Efgartigimod IV Fixed Cycles (n=17)	Efgartigimod IV Q2W (n=52) 57.1 (16.5)						Efç	Efgartigimod IV Q2W			Efgartigimod IV Fixed Cycles vs Q2			
52.4 (16.1)					LS mean			LS mean			LS estimate		te	
5 (29.4)	20 (38.5)		n				n							
9 (52.9)	34 (65.4)	mITT analysis set	17		13							-0 52		
7.4 (6.6)	6.9 (7.3)					7)	52			45)	(-2.1	(-2.104; 1.06		
6 (35.3)	17 (32.7)	^a The ANCOVA model inclu	del includes the treatment arm as a factor and the baseline MG-ADL total score as covariates.											
11 (64.7)	33 (63.5)		Table 3. Summary of TEAEs Safety Analysis Set											
0	2 (3.8)													
8.1 (2.2)	9.8 (3.3)			Efgartigimod IV			Efgartigimod IV Q2W (n=52, PYFU=20.9)			Efgartigimod IV Total population (n=69, PYFU=27.8)				
			(n=17, PYFU=6.9)											
17 (100.0)	39 (75.0)				n	%	ER⁵	n	%	ER⁵	n	%	ER⁵	
0	13 (25.0)	TEAE			16	94.1	12.0	43	82.7	10.1	59	85.5	10.6	
		Serious TEAE					0.4	7	13.5	0.3	8	11.6	0.4	
10 (58.8)	30 (57.7)					17.6	1.3		13.5	0.4		14.5	0.6	
8 (47.1)	19 (36.5)		Discontinued due to TEAEs		-			1	1.9	<0.1	1	1.4	<0.1	
12 (70.6)	49 (94.2)	Most frequent TEAEs ^a												
0 (0)	17 (32.7)	COVID-19					0.3	11	21.2	0.5	13	18.8	0.5	
		Headache			5	29.4	1.2	8	15.4	0.6	13	18.8	0.8	
	Efgartigimod IV Fixed Cycles $(n=17)$ 52.4 (16.1) 5 (29.4) 9 (52.9) 7.4 (6.6) 6 (35.3) 11 (64.7) 0 8.1 (2.2) 10 (58.8) 8 (47.1)	Efgartigimod IV Fixed Cycles $(n=17)$ Efgartigimod IV Q2W $(n=52)$ $52.4 (16.1)$ $57.1 (16.5)$ $5 (29.4)$ $20 (38.5)$ $9 (52.9)$ $34 (65.4)$ $7.4 (6.6)$ $6.9 (7.3)$ $6 (35.3)$ $17 (32.7)$ $11 (64.7)$ $33 (63.5)$ 0 $2 (3.8)$ $8.1 (2.2)$ $9.8 (3.3)$ $17 (100.0)$ $39 (75.0)$ 0 $13 (25.0)$ $10 (58.8)$ $30 (57.7)$ $8 (47.1)$ $19 (36.5)$ $12 (70.6)$ $49 (94.2)$	Fixed Cycles (n=17)Efgartigimod IV Q2W (n=52) $52.4 (16.1)$ $57.1 (16.5)$ $5 (29.4)$ $20 (38.5)$ $9 (52.9)$ $34 (65.4)$ $6.9 (7.3)$ $6 (35.3)$ $17 (32.7)$ $11 (64.7)$ $33 (63.5)$ 0 $2 (3.8)$ $8.1 (2.2)$ $9.8 (3.3)$ $17 (100.0)$ $39 (75.0)$ 0 $13 (25.0)$ TEAE Serious TEAE Grade ≥ 3 TEAE Fatal TEAE $10 (58.8)$ $30 (57.7)$ $8 (47.1)$ $19 (36.5)$ $12 (70.6)$ $49 (94.2)$ $0 (0)$ $17 (32.7)$	Efgartigimod IV Fixed Cycles (n=17) Efgartigimod IV Q2W (n=52) Image: Comparison of the comparison	Efgartigimod IV Fixed Cycles (n=17) Efgartigimod IV Q2W (n=52) Image: Colored Colore	Efgartigimod IV Fixed Cycles (n=17) Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W (n=52) 52.4 (16.1) 57.1 (16.5) 5 (29.4) 20 (38.5) 9 (52.9) 34 (65.4) 7.4 (6.6) 6.9 (7.3) 6 (35.3) 17 (32.7) 11 (64.7) 33 (63.5) 0 2 (3.8) 8.1 (2.2) 9.8 (3.3) 10 (58.8) 30 (57.7) 8 (47.1) 19 (36.5) 12 (70.6) 49 (94.2) 0 (0) 17 (32.7)	Efgartigimod IV Fixed Cycles (n=17) Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W (n=52) 52.4 (16.1) 57.1 (16.5) 5 5 (29.4) 20 (38.5) 9 (52.9) 34 (65.4) 7.4 (6.6) 6.9 (7.3) 6 (35.3) 17 (32.7) 11 (64.7) 33 (63.5) 0 2 (3.8) 8.1 (2.2) 9.8 (3.3) 10 (58.8) 30 (57.7) 8 (47.1) 19 (36.5) 12 (70.6) 49 (94.2) 0 (0) 17 (32.7)	Efgartigimod IV (n=17) Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W (n=52) Efgartigimod IV (n=17) In I T analysis set In I T analysis (n=17) In I I I analysis (n=17) In I I I I I I I I I I I I I I I I I I I	Efgartigimod IV Fixed Cycles (n=7) Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W (n=62) Efgartigimod IV Q2W (n=62) Efgartigimod IV Fixed Cycles Efgartigi Q2I 52.4 (16.1) 57.1 (16.5) 5 (29.4) 20 (38.5) n LS mean (95% Cl) n LS (95% Cl) n n LS (95% Cl) n n LS (95% Cl) N n LS (95% Cl) <td>Efgartigimod IV (n=17) Efgartigimod IV (22W (n=52) Efgartigimod IV (22W (n=7) Efgartigimod IV (22W Efgartigimod IV (22W Efgartigimod IV (22W Efgartigimod IV (22W 52.4 (16.1) 57.1 (16.5) 5 (29.4) 20 (38.5) n LS mean (95% Cl) n LS mean (95% Cl) n LS mean (95% Cl) 9 (52.9) 34 (65.4) n LS mean (95% Cl) n LS mean (95% Cl) 17 -5.13 (-6.499; -3.767) 52 -4.61 (-5.383; -3.84 6 (35.3) 17 (32.7) 11 (64.7) 33 (63.5) 0 2 (3.8) 17 etal the treatment am as a fracer and the baseline MG-ADL total score as construct (n=17, PYFU=5.9) Efgartigimod (n=52, PYFU 17 (100.0) 39 (75.0) n % Efgartigimod (n=17, PYFU=5.9) Efgartigimod (n=22, PYFU 10 (58.8) 30 (57.7) 8 (47.1) 19 (36.5) 16 94.1 12.0 43 82.7 12 (70.6) 49 (94.2) 0 (63.5) 0 1 1.9 0 0 12 (70.6) 49 (94.2) 0 (0) 1 1.9 0 1 1.9<!--</td--><td>Efgartigimod IV Fixed Cycles Efgartigimod IV Q2W (n=17) Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W Efgartigimod IV Q2W Efgartigimod IV Q2W 52.4 (16.1) 57.1 (16.5) n LS mean (95% Cl) n LS mean (95% Cl) LS mean (95% Cl) 9 (52.9) 34 (65.4) n LS mean (95% Cl) 17 -5.13 (-6.499; -3.767) 52 -4.61 (-5.383; -3.845) 6 (35.3) 17 (32.7) 11 (64.7) 33 (63.5) 0 2 (3.8) 8.1 (2.2) 9.8 (3.3) TeAE 1 5.9 0.4 7 13.5 0.3 10 (58.8) 30 (57.7) 8 (47.1) 19 (36.5) 3 17.6 1.3 7 13.5 0.4 12 (70.6) 49 (94.2) 0 (0) 17 (32.7) 1 1.9 0.4 7 13.5 0.3</td><td>Efgartigimod IV Fixed Cycles Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W Efgartigimod IV (n=52, 9% CI) Efgartigimo</td><td>Efgartigimod IV Fixed Cycles Efgartigimod IV Q2W Efgartigimod IV Q2W Efgartigimod IV Efgartigimod IV Q2W Efgartigimod IV Fixed Cycles Efgartigimod IV Q2W Efgartigimod IV (95% CI) Efgartig</td></td>	Efgartigimod IV (n=17) Efgartigimod IV (22W (n=52) Efgartigimod IV (22W (n=7) Efgartigimod IV (22W Efgartigimod IV (22W Efgartigimod IV (22W Efgartigimod IV (22W 52.4 (16.1) 57.1 (16.5) 5 (29.4) 20 (38.5) n LS mean (95% Cl) n LS mean (95% Cl) n LS mean (95% Cl) 9 (52.9) 34 (65.4) n LS mean (95% Cl) n LS mean (95% Cl) 17 -5.13 (-6.499; -3.767) 52 -4.61 (-5.383; -3.84 6 (35.3) 17 (32.7) 11 (64.7) 33 (63.5) 0 2 (3.8) 17 etal the treatment am as a fracer and the baseline MG-ADL total score as construct (n=17, PYFU=5.9) Efgartigimod (n=52, PYFU 17 (100.0) 39 (75.0) n % Efgartigimod (n=17, PYFU=5.9) Efgartigimod (n=22, PYFU 10 (58.8) 30 (57.7) 8 (47.1) 19 (36.5) 16 94.1 12.0 43 82.7 12 (70.6) 49 (94.2) 0 (63.5) 0 1 1.9 0 0 12 (70.6) 49 (94.2) 0 (0) 1 1.9 0 1 1.9 </td <td>Efgartigimod IV Fixed Cycles Efgartigimod IV Q2W (n=17) Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W Efgartigimod IV Q2W Efgartigimod IV Q2W 52.4 (16.1) 57.1 (16.5) n LS mean (95% Cl) n LS mean (95% Cl) LS mean (95% Cl) 9 (52.9) 34 (65.4) n LS mean (95% Cl) 17 -5.13 (-6.499; -3.767) 52 -4.61 (-5.383; -3.845) 6 (35.3) 17 (32.7) 11 (64.7) 33 (63.5) 0 2 (3.8) 8.1 (2.2) 9.8 (3.3) TeAE 1 5.9 0.4 7 13.5 0.3 10 (58.8) 30 (57.7) 8 (47.1) 19 (36.5) 3 17.6 1.3 7 13.5 0.4 12 (70.6) 49 (94.2) 0 (0) 17 (32.7) 1 1.9 0.4 7 13.5 0.3</td> <td>Efgartigimod IV Fixed Cycles Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W Efgartigimod IV (n=52, 9% CI) Efgartigimo</td> <td>Efgartigimod IV Fixed Cycles Efgartigimod IV Q2W Efgartigimod IV Q2W Efgartigimod IV Efgartigimod IV Q2W Efgartigimod IV Fixed Cycles Efgartigimod IV Q2W Efgartigimod IV (95% CI) Efgartig</td>	Efgartigimod IV Fixed Cycles Efgartigimod IV Q2W (n=17) Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W Efgartigimod IV Q2W Efgartigimod IV Q2W 52.4 (16.1) 57.1 (16.5) n LS mean (95% Cl) n LS mean (95% Cl) LS mean (95% Cl) 9 (52.9) 34 (65.4) n LS mean (95% Cl) 17 -5.13 (-6.499; -3.767) 52 -4.61 (-5.383; -3.845) 6 (35.3) 17 (32.7) 11 (64.7) 33 (63.5) 0 2 (3.8) 8.1 (2.2) 9.8 (3.3) TeAE 1 5.9 0.4 7 13.5 0.3 10 (58.8) 30 (57.7) 8 (47.1) 19 (36.5) 3 17.6 1.3 7 13.5 0.4 12 (70.6) 49 (94.2) 0 (0) 17 (32.7) 1 1.9 0.4 7 13.5 0.3	Efgartigimod IV Fixed Cycles Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W (n=52) Efgartigimod IV Q2W Efgartigimod IV (n=52, 9% CI) Efgartigimo	Efgartigimod IV Fixed Cycles Efgartigimod IV Q2W Efgartigimod IV Q2W Efgartigimod IV Efgartigimod IV Q2W Efgartigimod IV Fixed Cycles Efgartigimod IV Q2W Efgartigimod IV (95% CI) Efgartig	


ANCOVA, analysis of covariance; CMI, clinically meaningful improvement; ER, event rate; Fc, fragment crystallizable region; FcRn, neonatal Fc receptor; gMG, generalized myasthenia gravis; Ig, immunoglobulin; IV, intravenous; LS, least squares; MG, myasthenia gravis; MG-ADL, Myasthenia Gravis Activities of Daily Living; MGFA, Myasthenia Gravis Foundation of America; mITT, modified intent-to-treat; MSE, minimal symptom expression; NSIST, nonsteroidal immunosuppressive therapy; PYFU, participant years of follow-up; Q2W, every other week; TEAE treatment-emergent adverse event.

REFERENCES

1. Sesarman A, et al. Cell Mol Life Sci. 2010;67(15):2533-2550. 2. Pyzik M, et al. Nat Rev Immunol. 2023;23(7):415-432. 3. Ulrichts P, et al. J Clin Invest. 2018;128(10):4372-4386. 4. Vaccaro C, et al. Nat Biotechnol. 2005;23(10):1283-1288. 5. Howard JF Jr, et al. Lancet Neurol. 2021;20(7):526-536. 6. Nixon AE, et al. Front Immunol. 2015;6:176. 7. Ward ES, et al. Front Immunol. 2022;13:892534. 8. Howard JF Jr, et al. Front Neurol. 2024;14:1284444.

Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part A of ADAPT NXT

METHODS





ng NSISTs, corticosteroids, and/or AChEIs. If receiving corticosteroids and/or NSISTs, must be on a stable dose for ≥1 month prior to screening. ^bAll participants entering Part B will be transitioned to Q2W with the option to extend to Q3W dosing

^aReported by ≥10% of total participants. ^bER was calculated as number of events/PYFU


ACKNOWLEDGMENTS AND DISCLOSURES: The authors gratefully acknowledge the ADAPT NXT trial participants and investigators. VB: AZ-Alexion, Grifols, CSL, UCB, argenx, Takeda, Octapharma, Akcea, Momenta (J&J), Immunovant, Ionis, and Viela. YH: no disclosures. KG: Alexion, argenx, Strongbridge, and UCB. GS: Alexion, argenx, UCB, Immunovant, and Biogen. AAH: argenx, Alexion, VielaBio, UCB, Genentech, Regeneron, and Sanofi. KGC: Alnylam, Amicus, argenx, Biogen, CSL Behring, Ipsen, Janssen, Lupin, Pfizer, Roche, Sanofi-Genzyme, and UCB. EC-V: argenx, UCB, Alexion, and Janssen. EB, DG, AS, RHJ, and DH: argenx. RM: Alexion, argenx, Ra, BioMarin, Catalyst, UCB, Teva, Merck, Roche, and Biogen. The ADAPT NXT trial was funded by argenx. Medical writing and editorial support for this presentation was provided by PRECISION Value & Health and funded by argenx.

Vera Bril,^{1,2} Yessar Hussain,³ Kelly Gwathmey,⁴ Gregory Sahagian,⁵ Ali A. Habib,⁶ Kristl G. Claeys,⁷ Elena Cortés-Vicente,⁸ Edward Brauer,⁹ Deborah Gelinas,⁹ Anne Sumbul,⁹ Rosa H. Jimenez,⁹ Daniela Hristova,⁹ Renato Mantegazza¹⁰ ¹Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Austin, Texas, USA; ⁴Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA; ⁵The Neurology Center of Southern California, USA; ⁶Department of Neurology, University of California, USA; ⁶Department of Neurology, University of California, Irvine, California, USA; ⁶Department of Neurology, University of California, Irvine, California, USA; ⁶Department of Neurology, University of California, USA; ⁶Department of Neurology, University of California, Irvine, California, USA; ⁶Department of Neurology, University of California, USA; ⁶Department of Neurology, University of California, Irvine, California, USA; ⁶Department of Neurology, University of California, Irvine, California, USA; ⁶Department of Neurology, University of California, USA; ⁶Department of Neurology, University of California, Irvine, Irvine, California, USA; ⁶Department of Neurology, University of California, USA; ⁶Department of Neurology, University of California, Irvine, Ir Barcelona, Spain; ⁹argenx, Ghent, Belgium; ¹⁰Department of Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy






^aSolid data points indicate weeks in which efgartigimod was administered and open data points indicate weeks in which efgartigimod was not administered in each respective dosing regimen. ^bMixed model for repeated measurements with treatment, visit and treatment by visit interaction as fixed effects, and baseline total MG-ADL score as covariate.







Total IgG and AChR-Ab Level Changes From Baseline

The mean (SE) percent reduction in total IgG observed at Week 4 was -64.8% (1.9) for the Fixed Cycles arm and -67.6% (1.1) for the Q2W arm The mean percent changes from baseline in total IgG levels ranged between -58.0% and -67.6% for the Q2W arm across the 21 weeks

Mean (SE) percent changes from baseline in AChR-Ab levels observed at Week 4 were -52.7% (4.1) and -58.8% (1.8) for the Fixed Cycles and Q2W arms, respectively - The mean percent changes from baseline in total AChR-Ab levels ranged between -45.0% and -58.8% for the Q2W arm across the 21 weeks

